Last reviewed · How we verify
Proleukin
At a glance
| Generic name | Proleukin |
|---|---|
| Also known as | recombinanat interleukin-2, rIL-2, Interleukin 2, Proleukin = Interleukin II, Aldesleukin |
| Sponsor | University of Minnesota |
| Target | Interleukin-2 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Acute myeloid leukemia, disease
- Metastatic malignant melanoma
- Metastatic renal cell carcinoma
Common side effects
- Hypotension
- Hyperbilirubinemia
- Dyspnea
- Rash
- Diarrhea
- Oliguria
- Chills
- Vomiting
- Thrombocytopenia
- Nausea
- Confusional state
- Increased creatinine
Serious adverse events
- Fatal adverse reactions
- Capillary Leak Syndrome
- Cardiac arrest
- Myocardial infarction
- Pulmonary embolism
- Cerebrovascular accident
- Hepatic failure
- Renal failure
- Respiratory failure
- Sepsis
Key clinical trials
- Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (PHASE1, PHASE2)
- Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers (PHASE1, PHASE2)
- A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab (PHASE2)
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies (PHASE1)
- T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer (PHASE2)
- Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer (PHASE2)
- Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma (PHASE2)
- Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |